Stocks · News reference
Short seller BMF Capital disclosed a short position in SELLAS Life Sciences, arguing the market has 'dangerously overvalued' the biotech.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Company received a Staff Delisting Determination (the "Staff Determination"), dated August 3, 2026, from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq"), stating that
Nasdaq announced on August 3, 2026, that it will delist Magnitude International Ltd. (MAGH) from the Nasdaq Stock Market on August 12, 2026, unless the company appeals. The delisting follows a temporary trading suspension by the SEC in December 2025. Trading in the company's securities will remain halted until any appeal is resolved.
The Nasdaq Stock Market (NASDAQ:NDAQ) announced today that it has notified Magnitude International Ltd. (NASDAQ:MAGH) that its securities will be delisted from the Nasdaq Stock Market LLC on August 12, 2026, unless the
Revolution Medicines, Inc. (NASDAQ:RVMD), a global, commercial-stage oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers, today announced that
Revolution Medicines announced publication of Phase 1/2 clinical trial data for RASONQUE (daraxonrasib) in previously treated RAS mutant non-small cell lung cancer in the New England Journal of Medicine. The trial showed a 42% objective response rate and 16.0 months median overall survival in a docetaxel-naïve subgroup, with a manageable safety profile. Results support the ongoing Phase 3 RASolve 301 trial.
Bernie Sanders blasts Big Pharma over $400,000 cancer drugs, warning soaring treatment costs can push patients into financial ruin.